Skip to search formSkip to main contentSkip to account menu

Zarnestra

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tipifarnib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation
Zoledronic acid (ZOL) has proved activity in bone metastases from prostate cancer through inhibition of mevalonate pathway and of… 
2007
2007
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro‐apoptotic activity of interferon‐α through the inhibition of multiple survival pathways
Interferon α (IFNα) induces an EGF‐Ras→Raf‐1→Erk dependent survival pathway counteracting apoptosis induced by the cytokine. In… 
2007
2007
Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute…
The prognosis of older adults with acute myeloid leukemia (AML) has not improved over the last three decades, despite the… 
2006
2006
Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
The ability of the farnesyl transferase inhibitor R115777 to act as a cancer therapeutic/preventive agent and to modulate… 
2005
2005
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
2004
2004
High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).
R115777 is an oral selective inhibitor of farnesyltransferase which disrupts critical signaling pathways resulting in… 
2004
2004
Digital gangrene and Raynaud's phenomenon as complications of lung adenocarcinoma.
Review
2004
Review
2004
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Farnesyltransferase (FT) inhibitors were originally designed as anticancer agents, and were thought to act by inhibiting the… 
2003
2003
Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777.
PURPOSE Inhibitors of farnesyltransferase (e.g., R115777) are being developed for therapy and prevention of various cancers. The… 
Review
2002
Review
2002
Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
Acute leukemia carries a poor prognosis, especially in older patients, emphasizing the need for novel therapies. Reasons for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)